Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. grew its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 15.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,136,332 shares of the company's stock after purchasing an additional 288,402 shares during the quarter. Vanguard Group Inc. owned approximately 4.07% of Janux Therapeutics worth $114,379,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in shares of Janux Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company's stock valued at $30,107,000 after buying an additional 38,490 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Janux Therapeutics by 16.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 273,135 shares of the company's stock valued at $14,624,000 after purchasing an additional 38,944 shares in the last quarter. Victory Capital Management Inc. lifted its position in Janux Therapeutics by 715.0% during the fourth quarter. Victory Capital Management Inc. now owns 242,409 shares of the company's stock valued at $12,979,000 after purchasing an additional 212,664 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in Janux Therapeutics by 492.2% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 205,167 shares of the company's stock worth $10,771,000 after buying an additional 170,520 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after buying an additional 144,883 shares in the last quarter. Institutional investors own 75.39% of the company's stock.

Remove Ads

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the transaction, the insider now owns 82,139 shares of the company's stock, valued at approximately $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of Janux Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The stock was bought at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the purchase, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. This trade represents a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 29.40% of the company's stock.

Analyst Upgrades and Downgrades

JANX has been the topic of several recent research reports. Wedbush reiterated an "outperform" rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. Scotiabank decreased their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $92.44.

Janux Therapeutics Price Performance

Janux Therapeutics stock traded up $1.93 during mid-day trading on Friday, reaching $28.80. The stock had a trading volume of 2,018,926 shares, compared to its average volume of 855,615. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -24.62 and a beta of 3.27. Janux Therapeutics, Inc. has a one year low of $22.52 and a one year high of $71.71. The company has a 50-day moving average price of $31.72 and a two-hundred day moving average price of $44.14.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.